AR018622A1 - Compuestos (s)-(-)-1-[1-(4-sustituido o no sustituido, 2-metoxifenil)piperid-4-il]-n-(7-trifluorometil-2,3-dihidro-1,4-benzodioxin-2-il metil)metilamina,composiciones farmaceuticas que los comprenden, su uso para elaborar un medicamento y procedimiento para prepararlos - Google Patents
Compuestos (s)-(-)-1-[1-(4-sustituido o no sustituido, 2-metoxifenil)piperid-4-il]-n-(7-trifluorometil-2,3-dihidro-1,4-benzodioxin-2-il metil)metilamina,composiciones farmaceuticas que los comprenden, su uso para elaborar un medicamento y procedimiento para prepararlosInfo
- Publication number
- AR018622A1 AR018622A1 ARP990102619A ARP990102619A AR018622A1 AR 018622 A1 AR018622 A1 AR 018622A1 AR P990102619 A ARP990102619 A AR P990102619A AR P990102619 A ARP990102619 A AR P990102619A AR 018622 A1 AR018622 A1 AR 018622A1
- Authority
- AR
- Argentina
- Prior art keywords
- compound
- prepare
- formula
- compounds
- piperid
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 8
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 title 2
- 229940126601 medicinal product Drugs 0.000 title 1
- 239000003814 drug Substances 0.000 abstract 3
- 208000024827 Alzheimer disease Diseases 0.000 abstract 2
- 239000002904 solvent Substances 0.000 abstract 2
- 208000011117 substance-related disease Diseases 0.000 abstract 2
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 206010010774 Constipation Diseases 0.000 abstract 1
- 208000020401 Depressive disease Diseases 0.000 abstract 1
- 206010013654 Drug abuse Diseases 0.000 abstract 1
- 208000030814 Eating disease Diseases 0.000 abstract 1
- 208000027776 Extrapyramidal disease Diseases 0.000 abstract 1
- 208000019454 Feeding and Eating disease Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 208000008238 Muscle Spasticity Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 206010033664 Panic attack Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 206010039966 Senile dementia Diseases 0.000 abstract 1
- 201000001880 Sexual dysfunction Diseases 0.000 abstract 1
- 208000000323 Tourette Syndrome Diseases 0.000 abstract 1
- 208000016620 Tourette disease Diseases 0.000 abstract 1
- 208000022531 anorexia Diseases 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 206010003119 arrhythmia Diseases 0.000 abstract 1
- 230000006793 arrhythmia Effects 0.000 abstract 1
- 208000026106 cerebrovascular disease Diseases 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 206010061428 decreased appetite Diseases 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 235000014632 disordered eating Nutrition 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 206010013663 drug dependence Diseases 0.000 abstract 1
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 201000001421 hyperglycemia Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 210000000607 neurosecretory system Anatomy 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 208000019906 panic disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 231100000872 sexual dysfunction Toxicity 0.000 abstract 1
- 208000018198 spasticity Diseases 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9811879.7A GB9811879D0 (en) | 1998-06-03 | 1998-06-03 | Therapeutic agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR018622A1 true AR018622A1 (es) | 2001-11-28 |
Family
ID=10833098
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP990102619A AR018622A1 (es) | 1998-06-03 | 1999-06-03 | Compuestos (s)-(-)-1-[1-(4-sustituido o no sustituido, 2-metoxifenil)piperid-4-il]-n-(7-trifluorometil-2,3-dihidro-1,4-benzodioxin-2-il metil)metilamina,composiciones farmaceuticas que los comprenden, su uso para elaborar un medicamento y procedimiento para prepararlos |
Country Status (20)
| Country | Link |
|---|---|
| EP (1) | EP1087964A1 (tr) |
| JP (1) | JP2002517392A (tr) |
| KR (1) | KR20010052526A (tr) |
| CN (1) | CN1304408A (tr) |
| AR (1) | AR018622A1 (tr) |
| AU (1) | AU4369599A (tr) |
| BG (1) | BG104988A (tr) |
| BR (1) | BR9910927A (tr) |
| CA (1) | CA2333756A1 (tr) |
| CO (1) | CO5021190A1 (tr) |
| GB (1) | GB9811879D0 (tr) |
| HR (1) | HRP20010005A2 (tr) |
| HU (1) | HUP0102233A2 (tr) |
| ID (1) | ID27067A (tr) |
| IL (1) | IL139552A0 (tr) |
| NO (1) | NO20006041D0 (tr) |
| PL (1) | PL344594A1 (tr) |
| SK (1) | SK17602000A3 (tr) |
| TR (1) | TR200003569T2 (tr) |
| WO (1) | WO1999062902A1 (tr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9915616D0 (en) * | 1999-07-05 | 1999-09-01 | Knoll Ag | Therapeutic agents |
| GB0007376D0 (en) * | 2000-03-28 | 2000-05-17 | Knoll Ag | Therapeutic agents |
| WO2001085168A1 (en) * | 2000-05-12 | 2001-11-15 | Solvay Pharmaceuticals B.V. | Use of compounds having combined dopamine d2, 5-ht1a and alpha adrenoreceptor agonistic action for treating cns disorders |
| AU2001263927B2 (en) * | 2000-05-12 | 2004-09-30 | Solvay Pharmaceuticals B.V. | Piperazine and piperidine compounds |
| BRPI0608353A2 (pt) | 2005-02-17 | 2009-12-01 | Wyeth Corp | derivados de indol, benzotiofeno, benzofurano e indeno cicloalquilfundidos |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2681325B1 (fr) * | 1991-09-16 | 1993-12-17 | Fabre Medicament Pierre | Derives de l'aminomethyl-4 piperidine, leur preparation et leur application en therapeutique. |
| FR2701479B1 (fr) * | 1993-02-11 | 1995-05-12 | Pf Medicament | Nouveaux dérivés hétérocycliques de l'aminométhyl-4 pipéridine, leur préparation et leur application en thérapeutique. |
| GB9318431D0 (en) * | 1993-09-06 | 1993-10-20 | Boots Co Plc | Therapeutic agents |
| GB9514380D0 (en) * | 1995-07-13 | 1995-09-13 | Knoll Ag | Therapeutic agents |
-
1998
- 1998-06-03 GB GBGB9811879.7A patent/GB9811879D0/en not_active Ceased
-
1999
- 1999-05-26 HR HR20010005A patent/HRP20010005A2/hr not_active Application Discontinuation
- 1999-05-26 BR BR9910927-1A patent/BR9910927A/pt not_active IP Right Cessation
- 1999-05-26 SK SK1760-2000A patent/SK17602000A3/sk unknown
- 1999-05-26 IL IL13955299A patent/IL139552A0/xx unknown
- 1999-05-26 TR TR2000/03569T patent/TR200003569T2/tr unknown
- 1999-05-26 PL PL99344594A patent/PL344594A1/xx not_active Application Discontinuation
- 1999-05-26 JP JP2000552113A patent/JP2002517392A/ja active Pending
- 1999-05-26 AU AU43695/99A patent/AU4369599A/en not_active Abandoned
- 1999-05-26 KR KR1020007013670A patent/KR20010052526A/ko not_active Withdrawn
- 1999-05-26 HU HU0102233A patent/HUP0102233A2/hu unknown
- 1999-05-26 CA CA002333756A patent/CA2333756A1/en not_active Abandoned
- 1999-05-26 CN CN99806908A patent/CN1304408A/zh active Pending
- 1999-05-26 EP EP99926434A patent/EP1087964A1/en not_active Ceased
- 1999-05-26 ID IDW20002519A patent/ID27067A/id unknown
- 1999-05-26 WO PCT/EP1999/003648 patent/WO1999062902A1/en not_active Application Discontinuation
- 1999-06-03 CO CO99035020A patent/CO5021190A1/es unknown
- 1999-06-03 AR ARP990102619A patent/AR018622A1/es not_active Application Discontinuation
-
2000
- 2000-11-27 BG BG104988A patent/BG104988A/bg unknown
- 2000-11-29 NO NO20006041A patent/NO20006041D0/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| HRP20010005A2 (en) | 2001-12-31 |
| KR20010052526A (ko) | 2001-06-25 |
| SK17602000A3 (sk) | 2001-08-06 |
| WO1999062902A1 (en) | 1999-12-09 |
| IL139552A0 (en) | 2002-02-10 |
| CO5021190A1 (es) | 2001-03-27 |
| AU4369599A (en) | 1999-12-20 |
| BR9910927A (pt) | 2001-02-20 |
| JP2002517392A (ja) | 2002-06-18 |
| EP1087964A1 (en) | 2001-04-04 |
| PL344594A1 (en) | 2001-11-05 |
| TR200003569T2 (tr) | 2001-04-20 |
| CA2333756A1 (en) | 1999-12-09 |
| CN1304408A (zh) | 2001-07-18 |
| ID27067A (id) | 2001-02-22 |
| BG104988A (bg) | 2001-11-30 |
| GB9811879D0 (en) | 1998-07-29 |
| HUP0102233A2 (hu) | 2002-05-29 |
| NO20006041L (no) | 2000-11-29 |
| NO20006041D0 (no) | 2000-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2435432B3 (en) | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | |
| DE60126344T2 (de) | Isoindolimid-verbindungen, zusammensetzungen und verwendungen | |
| JPH09502431A (ja) | 治療薬剤としての二環式芳香族化合物 | |
| EP2308562B1 (en) | Azetidine ring compounds and drugs comprising the same | |
| CN1972907A (zh) | 磺酰胺化合物 | |
| JPS5995269A (ja) | 抗てんかん性医薬品 | |
| CA2596355A1 (en) | Tumor necrosis factor inhibitors | |
| FR2899586A1 (fr) | Dimeres de derives d'artemisinine, leur preparation et leur application en therapeutique | |
| CN1094936C (zh) | 新黄酮化合物、制备它们的方法以及含有它们的药物组合物 | |
| US20190084909A1 (en) | Fluorinated cbd compounds, compositions and uses thereof | |
| Varró et al. | The First Enantioselective Total Synthesis of (−)-trans-Dihydronarciclasine | |
| CN103097355A (zh) | 用于治疗皮肤病的新的喹啉酯 | |
| AR064134A1 (es) | Derivados de 2-aminoquinolina, un proceso para su preparacion, una composicion farmaceutica que los comprende y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por el antagonismo de los receptores 5-ht5a. | |
| Modi et al. | Potential anticancer agents. III. Schiff bases from benzaldehyde nitrogen mustards and aminophenylthiazoles | |
| Augstein et al. | Adrenergic neurone blocking agents derived from 1, 4-benzodioxan | |
| CN102134245A (zh) | 四氢异喹啉类化合物及其制备方法和用途 | |
| AR018622A1 (es) | Compuestos (s)-(-)-1-[1-(4-sustituido o no sustituido, 2-metoxifenil)piperid-4-il]-n-(7-trifluorometil-2,3-dihidro-1,4-benzodioxin-2-il metil)metilamina,composiciones farmaceuticas que los comprenden, su uso para elaborar un medicamento y procedimiento para prepararlos | |
| WO2007144487A2 (fr) | Molecules duales contenant un derive peroxydique, leur synthese et leurs applications therapeutiques | |
| DE4341402A1 (de) | N-substituierte Azabicycloheptan-Derivate, ihre Herstellung und Verwendung | |
| JPS5980668A (ja) | Ｎ−アリル化オキサゾリジン−２−オンの光学活性な誘導体、該誘導体の製法及び該誘導体による薬剤 | |
| JPH07505120A (ja) | チアフィゾベニンのカルバミン酸類縁化合物、医薬品用組成物、ならびにコリンエステラーゼ阻害方法 | |
| US20040039023A1 (en) | Therapeutic agents | |
| CN115160341A (zh) | 苯并噁嗪类化合物及其药物用途 | |
| CN106883225A (zh) | 一种具有1,2,4‑恶二唑‑结构片段的香豆素衍生物及其应用 | |
| CN1445217A (zh) | 取代的四氢异喹啉衍生物、其制备方法及含有它们的药物组合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |